What is the 13F Pro Quality Score for IDXX?

13F Pro ranks IDEXX LABORATORIES INC /DE (IDXX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IDXX's current score at https://13fpro.ai/company/IDXX (free sign-up required for the full ranking).

Where does 13F Pro source IDXX data?

All IDEXX LABORATORIES INC /DE fundamentals and ownership data come directly from SEC EDGAR. IDEXX LABORATORIES INC /DE files with the SEC under CIK 874716. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IDXX in?

IDEXX LABORATORIES INC /DE (IDXX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives IDXX's revenue?

Per IDEXX LABORATORIES INC /DE's latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: CAG (Companion Animal Group) ($1,118.2M, +9.4% YoY); CAG Diagnostics recurring revenue ($974.7M, +11.0% YoY); Water ($58.6M, +14.8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/IDXX.

What are IDXX's largest expenses?

IDEXX LABORATORIES INC /DE's latest 10-Q reports these as the largest expense items: Sales and marketing ($171.3M, +6.3% YoY); General and administrative ($116.8M, +18.4% YoY); Research and development ($65.4M, +5.7% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is IDXX research updated on 13F Pro?

IDXX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IDEXX LABORATORIES INC /DE(IDXX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 874716 IDXX stock profile & AI dashboard →

13F Pro Quality Score

73.8/100

Rank #128 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

56.9/100

Profitability

84.7/100

Balance Sheet

98.7/100

Earnings Quality

66.3/100

Free Cash Flow

81.2/100

Institutional Flow

76.4/100

Revenue Scale

76.6/100

Dilution Risk

48.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IDXX Scores 74/100

exact factor attribution · 2026-09-11

IDXX's composite is driven by profitability and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+5.2 pts

85th pct

Capital efficiency

+4.9 pts

99th pct

Free cash flow

+4.7 pts

81th pct

Scale

+4.0 pts

77th pct

Earnings quality

+1.6 pts

66th pct

Revenue growth

+1.4 pts

57th pct

Institutional flow

+1.3 pts

76th pct

Earnings growth

+0.8 pts

67th pct

Shareholder dilution

-0.1 pts

48th pct

Latest change (2026-08-04): 74 → 72 · ↓ Revenue growth 60→51

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IDXX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IDEXX LABORATORIES INC /DE (IDXX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IDXX at 73.8/100 on a 32-signal composite quality model, placing it at rank #128 of 2,961 stocks — the top 5% of the AI-ranked universe. IDXX scores in the top quartile across balance sheet strength (98.7), profitability (84.7), free cash flow (81.2). Shareholder dilution risk is elevated at 48.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IDEXX LABORATORIES INC /DE reports quarterly revenue of $1.2B, net income of $338.4M, an operating margin of 35.0%. Top institutional holders of IDXX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. IDXX trades on the Nasdaq exchange and files with the SEC under CIK 874716. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IDXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IDEXX LABORATORIES INC /DE directly from SEC EDGAR. IDEXX LABORATORIES INC /DE's 13F Pro composite quality score has ranged between 69 and 79 since 2021, currently 73.8 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about IDEXX LABORATORIES INC /DE

Quirks, history, and lore behind IDXX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on Nasdaq · headquartered in Maine.
2
The Numbers
Annual revenue around $3.5 billion, with operating margins that make pharma executives jealous — because it sells tests and instruments, not pills.
3
The History
Founded in the 1980s, it carved out a dominant niche by focusing exclusively on veterinary diagnostics — a market most healthcare giants ignored entirely.
4
The Secret
The real money is a classic razor-and-blades model: place the analyzer in the clinic, then sell a steady stream of consumable test cartridges for years.
5
The Lore
It is essentially the dominant monopoly of pet diagnostics — vets rely on it the way hospitals rely on Quest, and switching costs keep them locked in for life.
6
The Giveaway
If your dog just got blood work at the vet, there's a very good chance the machine was a Catalyst One and the bill was processed through this company's IDEXX VetLab platform.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving IDXX's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from IDEXX LABORATORIES INC /DE's 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue rose 9.7% to $1,216.6M on 11.0% CAG Diagnostics recurring growth, with gross margin up 140 bps to 64.0% despite a 19.5% drop in instrument revenue.

Biggest Revenue Drivers

CAG (Companion Animal Group)$1,118.2M+9.4% YoY

Higher IDEXX VetLab consumables and reference laboratory volumes plus higher realized prices

Water$58.6M+14.8% YoY

Higher volumes in the Americas and Europe, led by Colilert coliform and E. coli test demand

Biggest Revenue Drivers

Total revenue: $1,216.6M+9.7% YoY

CAG (Companion Animal Group)$1,118.2M+9.4% YoY

Higher IDEXX VetLab consumables and reference laboratory volumes plus higher realized prices

Within CAG (Companion Animal Group)

CAG Diagnostics recurring revenue$974.7M+11.0% YoY

Higher sales volumes of VetLab consumables and reference lab testing, plus higher realized prices

CAG Diagnostics capital - instruments$47.2M-19.5% YoY

Lower placements of the IDEXX inVue Dx Analyzer versus broad commercial availability in Q2 2025

Water$58.6M+14.8% YoY

Higher volumes in the Americas and Europe, led by Colilert coliform and E. coli test demand

LPD (Livestock, Poultry and Dairy)$35.2M+10.8% YoY

Higher test volumes, particularly in the Americas, and higher realized prices

Largest Expense Items

Sales and marketing$171.3M+6.3% YoY

Higher personnel-related and travel costs and costs related to commercial expansion

General and administrative$116.8M+18.4% YoY

Higher personnel costs and higher depreciation/amortization from technology and infrastructure investments

Research and development$65.4M+5.7% YoY

Higher personnel-related costs

Margins: Gross margin rose 140 bps to 64.0% on proportionally higher VetLab consumable and reference lab volume, mix from lower premium instrument revenue, productivity, and net price realization. Operating margin reached 35.0%.

Watch Items from the Filing

CAG Diagnostics capital - instrument revenue fell 19.5% to $47.2M on lower IDEXX inVue Dx Analyzer placements versus prior-year launch availability.
Rapid assay revenue grew just 1.3% to $101.6M as lower vector-borne disease testing and a shift of pancreatic lipase testing to Catalyst offset price.
Multi-year customer commitment arrangements represent approximately $5.3 billion of estimated future revenue, with 14% expected in the remainder of 2026.
Credit Facility borrowings rose to $519.0M from $398.0M; $75.0M 2026 Senior Notes due September 4, 2026, and $75.0M 2027 Notes due February 2027.
International revenue is 36% of the total at $443.6M; a 1% U.S. dollar strengthening would reduce revenue by roughly $8M and operating income by $3M.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.2B

Net Income

Q2 2026

$338.4M

Free Cash Flow

Q2 2026

$322.5M

Operating Margin

Q2 2026

35.0%

D/E Ratio

Q2 2026

0.28

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.4% YoY

$4.30BFY 2025

FY22 $3.37BFY23 $3.66BFY24 $3.90BFY25 $4.30B

Net Income

+19.3% YoY

$1.06BFY 2025

FY22 $679.1MFY23 $845.0MFY24 $887.9MFY25 $1.06B

Operating Income

+20.5% YoY

$1.36BFY 2025

FY22 $898.8MFY23 $1.10BFY24 $1.13BFY25 $1.36B

EPS (Diluted)

+22.6% YoY

$13.08FY 2025

FY22 $8.03FY23 $10.06FY24 $10.67FY25 $13.08

Total Assets

+1.7% YoY

$3.35BFY 2025

FY22 $2.75BFY23 $3.26BFY24 $3.29BFY25 $3.35B

Total Debt

-33.2% YoY

$525.0MFY 2025

FY22 $844.8MFY23 $773.2MFY24 $785.6MFY25 $525.0M

Op. Cash Flow

+27.2% YoY

$1.18BFY 2025

FY22 $543.0MFY23 $906.5MFY24 $929.0MFY25 $1.18B

Free Cash Flow

+30.8% YoY

$1.06BFY 2025

FY22 $394.1MFY23 $772.9MFY24 $808.1MFY25 $1.06B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.30B +10.4%	$3.90B +6.5%	$3.66B +8.7%	$3.37B +4.7%	$3.22B +18.8%	$2.71B
Net Income	$1.06B +19.3%	$887.9M +5.1%	$845.0M +24.4%	$679.1M -8.8%	$744.8M +28.0%	$581.8M
Operating Income	$1.36B +20.5%	$1.13B +2.8%	$1.10B +22.1%	$898.8M -3.6%	$932.0M +34.2%	$694.5M
EPS (Diluted)	$13.08 +22.6%	$10.67 +6.1%	$10.06 +25.3%	$8.03 -6.6%	$8.60 +28.2%	$6.71
Total Assets	$3.35B +1.7%	$3.29B +1.0%	$3.26B +18.7%	$2.75B +12.7%	$2.44B +6.2%	$2.29B
Total Debt	$525.0M -33.2%	$785.6M +1.6%	$773.2M -8.5%	$844.8M -8.7%	$925.7M -3.5%	$959.1M
Operating Cash Flow	$1.18B +27.2%	$929.0M +2.5%	$906.5M +66.9%	$543.0M -28.1%	$755.5M +16.6%	$648.1M
Free Cash Flow	$1.06B +30.8%	$808.1M +4.6%	$772.9M +96.1%	$394.1M -38.0%	$636.0M +17.5%	$541.1M

Get alerted when IDXX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IDEXX LABORATORIES INC /DE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IDXX

BlackRock, Inc.
$4.3B8,170,178 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.7B5,152,213 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.1B3,896,521 sh
STATE STREET CORP
$2.0B3,748,660 sh
Invesco Ltd.
$1.9B3,611,416 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3B2,562,886 sh
BAMCO INC /NY/
$1.0B1,976,778 sh
MORGAN STANLEY
$713.9M1,356,103 sh
Bank of New York Mellon Corp
$628.2M1,193,343 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$561.8M1,067,078 sh

Fund	Value	Shares
BlackRock, Inc.	$4.3B	8,170,178
VANGUARD CAPITAL MANAGEMENT LLC	$2.7B	5,152,213
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.1B	3,896,521
STATE STREET CORP	$2.0B	3,748,660
Invesco Ltd.	$1.9B	3,611,416
GEODE CAPITAL MANAGEMENT, LLC	$1.3B	2,562,886
BAMCO INC /NY/	$1.0B	1,976,778
MORGAN STANLEY	$713.9M	1,356,103
Bank of New York Mellon Corp	$628.2M	1,193,343
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$561.8M	1,067,078

Companies Similar to IDXX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SYK

STRYKER CORP

AI score

Very similar · 34 shared holders

Fundsmith LLP Capital Research Global Investors Clearbridge Investments, LLC

RMD

RESMED INC

AI score

Very similar · 29 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC WELCH & FORBES LLC AustralianSuper Pty Ltd

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 24 shared holders

Capital Research Global Investors Clearbridge Investments, LLC BAILLIE GIFFORD & CO

ZTS

Zoetis Inc.

AI score

Very similar · 27 shared holders

MONTRUSCO BOLTON INVESTMENTS INC.Epoch Investment Partners, Inc.Capital Research Global Investors

ISRG

INTUITIVE SURGICAL INC

AI score

Very similar · 36 shared holders

Capital Research Global Investors Alyeska Investment Group, L.P.Clearbridge Investments, LLC

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 25 shared holders

Capital Research Global Investors Clearbridge Investments, LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Very similar · 29 shared holders

Capital Research Global Investors WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Liontrust Investment Partners LLP

ABT

ABBOTT LABORATORIES

AI score

Very similar · 28 shared holders

Capital Research Global Investors Alyeska Investment Group, L.P.Holocene Advisors, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IDXX on your watchlist

Track score changes the day IDEXX LABORATORIES INC /DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IDXX a good stock to buy?

13F Pro's AI-powered analysis of IDEXX LABORATORIES INC /DE (IDXX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IDXX are available on the IDXX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IDXX is classified as a large company.

Which hedge funds own IDXX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IDXX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IDEXX LABORATORIES INC /DE's investment landscape.